Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$19.08 - $26.7 $472,745 - $661,545
-24,777 Reduced 62.79%
14,681 $374,000
Q1 2022

May 16, 2022

SELL
$21.19 - $40.01 $397,142 - $749,867
-18,742 Reduced 32.2%
39,458 $1.02 Million
Q4 2021

Feb 14, 2022

BUY
$30.97 - $54.03 $37,442 - $65,322
1,209 Added 2.12%
58,200 $2.44 Million
Q3 2021

Nov 15, 2021

SELL
$34.9 - $54.54 $122,045 - $190,726
-3,497 Reduced 5.78%
56,991 $2.48 Million
Q2 2021

Aug 16, 2021

SELL
$38.75 - $51.0 $197,547 - $259,998
-5,098 Reduced 7.77%
60,488 $2.86 Million
Q1 2021

May 14, 2021

SELL
$26.34 - $83.07 $462,346 - $1.46 Million
-17,553 Reduced 21.11%
65,586 $3.36 Million
Q4 2020

Feb 16, 2021

BUY
$25.51 - $43.38 $92,703 - $157,642
3,634 Added 4.57%
83,139 $2.23 Million
Q3 2020

Nov 13, 2020

BUY
$28.28 - $53.6 $2.25 Million - $4.26 Million
79,505 New
79,505 $2.73 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $1.28B
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Capital International, Inc. Portfolio

Follow Capital International, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Capital International, Inc. with notifications on news.